Investors Twice Shy on Cell Therapeutics
Looking Before You Leap
Birchenough also cautions against jumping to happy conclusions about the Stellar 3 study simply because Cell Therapeutics executives have pushed back the data timeline. He notes, correctly, that non-small cell lung cancer patients are a notoriously heterogeneous group, which means that other factors could be affecting the study, not the least of which may be that paclitaxel patients in the study's control arm are also living longer.
For Xyotax to succeed in this study, it must prove itself superior to paclitaxel, which as I said above, is well known as an effective cancer drug. By comparison, OSI Pharmaceuticals' Tarceva study had an easier hurdle to vault because the drug was only being compared with a placebo.
A price has yet to be set for Cell Therapeutics' follow-on offer, but the timing of the financing in front of the Stellar 3 study results will cause some investors to worry more, and it will underscore the company's weak balance sheet -- another reason investors have stayed away.At the end of the first quarter, Cell Therapeutics had $132 million in cash and marketable securities, but $190 million in convertible debt and negative shareholder's equity. Before this most recent financing, the company had enough cash to last though mid-2005. Lastly, let's not forget that Cell Therapeutics has not exactly been a poster child for pristine corporate governance. The company granted CEO Jim Bianco a $3.5 million loan in 2002, due April 2004. But Bianco, to date, hasn't been able to repay the obligation in full, although he's promised to make good on it. Bianco and the rest of company management also fly in a company-leased corporate jet, a tad expensive and unusual for a company its size. Don't look for Cell Therapeutics to exit from Wall Street's penalty box until, and if or when, Xyotax delivers.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV